Volume 22, Number 3—March 2016
Decreased Time to Treatment Initiation for Multidrug-Resistant Tuberculosis Patients after Use of Xpert MTB/RIF Test, Latvia
|Exposure: Xpert MTB/RIF||Stratifier: previous TB||Time ratio (95% CI), p value
|Model 1: 2-Strata Xpert, year as confounder||Model 2: 3-Strata Xpert||Model 3: 3-Strata Xpert, year as confounder|
|Conducted, rifampin-resistant TB||No||0.15 (0.11−0.21), <0.001||0.16 (0.12−0.21), <0.001||0.15 (0.11−0.20), <0.001|
|Conducted, negative result||No||NA||1.17 (0.62−2.22), 0.62||1.09 (0.57−2.09), 0.80|
|Conducted, rifampin-resistant TB||Yes||0.45 (0.27−0.77), 0.003||0.33 (0.20−0.54), <0.001||0.45 (0.27−0.76), 0.003|
|Conducted, negative result||Yes||NA||2.97 (1.07−8.28), 0.04||3.63 (1.27−10.37), 0.02|
*Three models of sensitivity of the association between Xpert MTB/RIF use and the time to MDR TB treatment initiation stratified by the effect modifier previous TB were used. Model 1 included year as a confounder (restricting the dataset to 2010–2012; 258 patients). Model 2 included persons who had negative results for rifampin resistance by Xpert MTB/RIF (387 patients). Model 3: models 1 and 2 assessed simultaneously (273 patients). A final model was adjusted for all variables except country of birth, social risk factors, and HIV status (plus year where stated). Median in baseline strata of Xpert MTB/RIF and previous tuberculosis was 41 days for all analyses. A positive result was rifampin-resistant TB, and a negative result was rifampin sensitivity or no TB detected. MTB, Mycobacterium tuberculosis; RIF, rifampin. MDR TB, multidrug-resistant tuberculosis; NA, not applicable.
1These authors contributed equally to this article.